Two major cardiology trials fail, a reality check for 'AI will cure all disease'
anshulkundaje · x · 2026-11-09
Two large secondary-prevention cardiovascular trials presented at #AHA26 and published in NEJM — an IL-6 antibody and an Lp(a) antisense oligonucleotide — showed no benefit overall or in any subgroup. Marios Georgakis notes that even compelling hypotheses like IL-6 and Lp(a) still must prove patient benefit in trials, a caution for those claiming AI will cure all disease in five years.
Related event: Two Major Cardiovascular Trials Fail, AI Offers Clues(2 posts)→
More from AGI Musings
- METR says it has 'convincing evidence' AI speeds up research — but the details are redacted — peterwildeford · 2026-11-09
- OpenAI co-founder Greg Brockman: frontier models with test-time compute are becoming the engine of scientific discovery — gdb · 2026-11-09
- Long-term memory vs. search is like L1 cache vs. RAM, argues zetalyrae — zetalyrae · 2026-11-09
- AI is eroding traditional moats: years of advantage now replicated in days — DeryaTR_ · 2026-11-09
- Epoch AI: 2027 chip supply could run 30–170M frontier AI agents, or 1.9B cheaper ones — Dr_Singularity · 2026-11-09
- White paper: moving beyond the AI compute arms race as big tech faces historic spending losses — ReportProfessional57 · 2026-11-09